Type 2 Diabetes Study Seeks Volunteers taking Metformin, With or Without up to 2 Other Oral Diabetes Medications.

 

We are currently seeking volunteers who are diagnosed with Type 2 Diabetes and who are treating with Metformin alone or in combination with a stable dose of DPP-IV’s and/or SGLT-2’s for 3 months.

DPP-IV: Januvia [Sitagliptin], Onglyza [Saxagliptin], Tradjenta [Linagliptin], and maybe more new ones.

SGLT-2: Farxiga [Dapagliflozin], Invokana [Canagliflozin], Jardiance [Empagliflozin], and maybe more new ones.

This is a study of an investigational once weekly basal insulin. Participants will be assigned to one of two groups: Half of all the participants will be on the investigational once weekly insulin and the other half will be on (FDA Approved) Daily Insulin Degludec (Tresiba) administered by insulin pen. Participants assigned to the Once Weekly insulin must make a weekly visit to the clinic where the injection will be administered by the study staff for the first 8 weeks. During weeks 9-12 the subject will come into the clinic on a weekly basis to self-administer the injection under staff supervision. During weeks 13-25, subjects will self-administer the once weekly injection at home. Participants assigned to Insulin Degludec (Tresiba) will administer a once daily injection at approximately the same time of day at home.

All participants will wear an Abbott Libre Pro CGM for 14 days on 3 separate occasions. This CGM will monitor their glucose continuously but will be blinded so both participant and study staff will NOT see blood glucose results. Participants must be willing to keep an electronic glucose diary, daily fasting blood glucose results, and periodic 6-point blood glucose profiles.

Please contact us for further details by filling out this volunteer form below or calling us at 1-888-478-8343.